Founded in 2019, Respiree’s technology is based on core sensor technology developed at the Singapore Bioimaging Consortium (SBIC), at A*STAR. Gurpreet Singh, Founder of Respiree and A*STAR scholar, shares how he turned a discovery in the lab into a device that could potentially save lives.

Local medical technology start-up Respiree aims to deploy respiratory bio-markers to predict worsening conditions in Covid-19 patients in isolation rooms.

Early identification and therapeutic intervention are key to reducing risk for individuals at risk of acute respiratory failure and pneumonia from COVID-19 – such is the core of the collaboration between the National University Hospital (NUH), NUS Yong Loo Lin School of Medicine (NUS Medicine) and Respiree Pte Ltd.